Efficacy of Resveratrol in Depression

Phase 4

Completed

• Conditions: Depression
• Interventions: Drug: Resveratrol Pill; Drug: Placebos

• Registration Number: NCT03384329
• Lead Sponsor: Russian Academy of Medical Sciences

Brief Summary

Patients with depression (target number - 60) receive resveratrol 500 mg or placebo (1:1) each morning daily for 1 month with primary outcome measures of the score change on depression rating scale HDRS-17 and change in SIRT1 activity in the blood measured 4 times over the study period (before, in the middle, after the intervention, and in 2 week follow up).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-12-11
• Study First Submitted QC: 2017-12-19
• Study First Posted: 2017-12-27
• Study Start: 2018-07-04
• Primary Completion: 2019-08-27
• Study Completion: 2019-09-18
• Results First Submitted: 2020-10-23
• Results First Submitted QC: 2020-10-23
• Status Verified: 2020-11
• Results First Posted: 2020-11-17
• Last Update Submitted: 2020-11-17
• Last Update Posted: 2020-12-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Resveratrol Pill	Resveratrol Pill	-
Placebo	Placebos	-

Primary Outcome Measures

Name	Time	Method
Change in Total HDRS-17 Score From Baseline to Week 4	4 weeks	Hamilton Depression Rating Scale 17 items, total score range 0-53 (53 - worse)
Change in SIRT1 Activity From Baseline to Week 4	4 weeks	SIRT1 is enzyme sirtuin-1 which activity is measured in the blood

Secondary Outcome Measures

Name	Time	Method
Change in Total BDI-II Score From Baseline to Week 4	4 weeks	Beck Depression Inventory 21 items, total score range 0-63 (63 - worse)

Trial Locations

Locations (1)

Lyubomir I. Aftanas; 🇷🇺 Novosibirsk, Russian Federation